［1］Smita Bhatia MD.Therapy-related myelodysplasia and acute myeloid leukemia［J］.Semin Oncol，2013，40(6):10.
［2］Abdelhameed A，Pond GR，Mitsakakis N，et al.Outcome of patients who deverop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that indude chemotherapy and/or radiation［J］.Cancer，2009，112:1513-1521.
［3］Mojtaba Akhtari，Vijaya Raj Bhatt，Pavan Kumar Tandra，et al.Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients［J］.Cancer Biol Ther，2013，14(12):1077-1088.
［4］Ravi Bhatia，H Joachim Deeg.Treatment-related myelodysplastic syndrome-molecular characteristics and therapy［J］.Curr Opin Hematol，2011，18(2):77-82.
［5］Yiming Chen，Zeev Estrov，Sherry Pierce，et al.Myeloid neoplasms after breast cancer:"therapy-related" not an independent poor prognostic factor［J］.Leuk Lymphoma，2015，56(4):1012-1019.
［6］Antonio C Wolff，Amanda L Blackford.Risk of marrow neoplasms after adjuvant breast cancer therapy:The national comprehensive cancer network experience［J］.J Clin Oncol，2015，33(4):340-348.
［7］H Sill，W Olipitz，A Zebisch，et al.Therapy-related myeloid neoplasms:Pathobiology and clinical characteristics［J］.Br J Pharmacol，2011，162(4):792-805.
［8］Anaespirito espirito S，Sergio C，Isabel F，et al.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia［J］.Oncol Lett，2016，12(1):262-268.
［9］Smith RE，Bryant J，DeCillis A，et al．Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer:The National Surgical Adjuvant Breast and Bowel Project Experience［J］.Clin Oncol，2003，21 (7):1195- 1204．
［10］Henry G Kaplan，Judith A Malmgren,Mary K Atwood.Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy:A registry cohort analysis 1990-2005［J］.BMC Cancer，2011，11:260.
［11］Maureen M,O'Brien，Sarah S,et al.Second malignant neoplasms in survivors of pediatric hodgkin's lymphoma treated with low-dose radiation and chemotherapy［J］.J Clin Oncol，2010，28(7):1232-1239.
［12］Bjrkholm M，Hultcrantz M，Derolf R.Leukemic transformation in myeloproliferative neoplasms:Therapy-related or unrelated［J］?Best Pract Res Clin Haematol，2014，27(2):141-153.
［13］Blum S，Martins F，Alberio L.Ruxolitinib in the treatment of polycythemia vera:Patient selection and special considerations［J］.J Blood Med，2016，7:205-215.
［14］Macías I.Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation:A case report and review literature［J］.Int J Surg Case Rep，2016，28:93-96.
［15］Alvarez-Larrán A，Kerguelen A，Hernández-Boluda JC，et al.Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera［J］.Br J Haematol，2016，172(5):786-793.
［16］Kundranda MN，Tibes R，Mesa RA.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia:Does anything work［J］?Curr Hematol Malig Rep，2012，7(1):78-86.